Financial Performance - Revenue for the year ended December 31, 2025, was $13,060,000, a decrease of 5% compared to $13,764,000 in 2024[6] - Loss attributable to owners of the company was $(15,437,000), a significant improvement of 68% from $(48,128,000) in the previous year[6] - The company reported a net loss attributable to shareholders of approximately $15.44 million for the year ending December 31, 2025, with current liabilities and total liabilities amounting to approximately $197.44 million and $181.62 million, respectively[23] - The company recorded an annual loss of $16 million in 2025, a significant reduction of 67.81% from the $48 million loss in 2024[15] - The gross profit for the year ended December 31, 2025, was about $1.48 million, down 31.8% from $2.17 million in 2024, with a gross margin of 11.32%[37][40] - The company’s Ibam project has an estimated resource of approximately 151 million tons with an average grade of 46.5% iron, with a mining period expected to exceed 26 years[36] Operational Efficiency - The company aims to strengthen cost control and inventory management to ensure cash flow remains within a controllable range[11] - The company has implemented strict cost control measures, including optimizing labor efficiency and conducting salary reviews, with no capital expenditures reported for the quarters ending September 30 and December 31, 2025[27] - The company is committed to sustainable development and compliance optimization of its mining assets while navigating market uncertainties[15] - The company is focused on enhancing its financial systems and project feasibility assessments to drive growth[189] Market Strategy - The plant stem cell business experienced a slight decline in sales revenue due to macroeconomic changes and market demand fluctuations[11] - The company continues to focus on research and development, optimizing product quality and expanding application scenarios in plant stem cell extraction[10] - Future strategies include enhancing operational efficiency and product value while adhering to green production principles[13] - The company is exploring the diversity of plant stem cell applications and expanding its product offerings to include skincare and beauty products[18] - The company maintains a B2B business model, supplying health products to health management platforms and distributors, which helps expand market coverage[19] Debt and Financial Management - The company has ongoing debt restructuring efforts, including comprehensive proposals for debt settlement and equity swaps, and has achieved a waiver of approximately $9.9 million in accrued interest, alleviating financial burdens[26] - The company aims to improve liquidity and advance debt restructuring in 2026, with ongoing communications with potential investors and financial institutions for viable restructuring solutions[30] Environmental and Social Responsibility - The company is committed to integrating sustainability concepts into daily operations and continuously seeks opportunities to improve performance and corporate strategy[139] - The company has updated its "green policy" to align with sustainable development goals, ensuring compliance with environmental regulations in Hong Kong, China, and Malaysia[140] - The company adheres to all relevant environmental laws and regulations, with no confirmed incidents of non-compliance reported[140] - The company encourages employee participation in community service to contribute to a sustainable and harmonious society[179] Corporate Governance - The board consists of three executive directors and three independent non-executive directors, ensuring compliance with corporate governance standards[84] - The company has adhered to the corporate governance code and has implemented measures to maintain accountability and transparency[79] - The audit committee reviewed the financial statements for the year ending December 31, 2025, confirming compliance with applicable accounting standards and regulations[93] - The company has established a shareholder communication policy to ensure equal treatment and timely information dissemination to all shareholders[114] Employee Management - The company employed 49 employees in 2025, an increase of 22.5% from 40 employees in 2024[159] - The employee turnover rate for those aged 30 or below was 10.20% in 2025, down from 15.00% in 2024[163] - The company has implemented policies to ensure a safe and healthy work environment, with no reported injuries in the fiscal years 2024 and 2025[165] - The company has a commitment to training, with 85% of management and 85% of other staff receiving training in 2025[170] Risk Management - The main risk identified for 2025 is the potential decrease in business due to economic recession or political environment changes, particularly affecting steel demand[108] - The company has established a corporate risk management framework since 2016, following the COSO framework for effective risk management[107] - The risk register is maintained to track all identified major risks, with assessments conducted at least annually[110]
恩典生命科技(02112) - 2025 - 年度业绩